Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's ...

Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize. Bourla found out at around 9 p.m. that ...

Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company’s up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer’s strategy for clinical ...

Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth ...

Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with ...

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ...

Amid Novo Nordisk and Pfizer’s whiplash contest for obesity biotech Metsera, Novo’s CEO has, quite literally, told its rival to put its money where its mouth is. | Amid Novo Nordisk and Pfizer’s ...

Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera, but said ...

Get the daily news here. Read the essential Danish news and topics of today - in English. Politiken Edition is your window to ...

But Doustdar also seems to recognize what he has in Novo Nordisk, the 100-year-old pharma that brought insulin to the masses, ...

Novo Nordisk A/S Chief Executive Officer Mike Doustdar may have lost out to Pfizer Inc. in a $10 billion takeover battle for ...